Centralized administration is critical for efficient program management, coordination, and execution. Core A (Administrative Core) will provide all the logistic, scientific, managerial, financial, and biostatistics support to facilitate and to coordinate the studies described in this IPCAVD program. Core A will ensure that all the Projects and Cores function optimally and adhere to the timelines described in this grant. Core A will organize conference calls every two weeks and regular in-person meetings, maintain regulatory approvals, provide fiscal and logistic oversight, manage subcontracts, coordinate meetings with the Scientific Advisory Board (SAB) and NIAID Program Officials to support this IPCAVD program, and provide centralized biostatistics support for all preclinical and clinical studies for this IPCAVD program. This detailed administration and management structure will ensure that all the studies remain focused on the overall objective to develop Ad26/Env vaccines for HIV-1. To accomplish these goals, we propose the following five Specific Aims:
Specific Aim 1. To coordinate communications, interactions, and operations among investigators, Projects, and Cores to facilitate the overall progress and goals of this IPCAVD program Specific Aim 2. To ensure and to maintain regulatory compliance Specific Aim 3. To provide detailed financial oversight and management Specific Aim 4. To coordinate meetings with the SAB and NIAID Program Officials Specific Aim 5. To provide centralized biostatistics support for this IPCAVD program

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Barouch, Dan H; Tomaka, Frank L; Wegmann, Frank et al. (2018) Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 392:232-243
Badamchi-Zadeh, Alexander; Moynihan, Kelly D; Larocca, Rafael A et al. (2018) Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy. J Immunol 201:2744-2752
Alter, Galit; Barouch, Dan (2018) Immune Correlate-Guided HIV Vaccine Design. Cell Host Microbe 24:25-33
Bricault, Christine A; Kovacs, James M; Badamchi-Zadeh, Alexander et al. (2018) Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. J Virol :
Whitney, James B; Lim, So-Yon; Osuna, Christa E et al. (2018) Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy. Nat Commun 9:5429
Borducchi, Erica N; Liu, Jinyan; Nkolola, Joseph P et al. (2018) Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563:360-364
Barouch, Dan H (2018) A step forward for HIV vaccines. Lancet HIV 5:e338-e339